Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes

Mobocertinib is an oral tyrosine kinase inhibitor (TKI) that selectively targets epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations. It is a structural analog of the third-generation TKI osimertinib, which targets EGFR T790M mutant non-small cell lung cancer (NSCLC); however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Abram, Ganti, Apar Kishor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349594/
https://www.ncbi.nlm.nih.gov/pubmed/37456145
http://dx.doi.org/10.2147/OTT.S374489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349594/
https://www.ncbi.nlm.nih.gov/pubmed/37456145
http://dx.doi.org/10.2147/OTT.S374489

Ejemplares similares